Combination therapy in multiple sclerosis

@article{Milo2011CombinationTI,
  title={Combination therapy in multiple sclerosis},
  author={R. Milo and H. Panitch},
  journal={Journal of Neuroimmunology},
  year={2011},
  volume={231},
  pages={23-31}
}
  • R. Milo, H. Panitch
  • Published 2011
  • Medicine
  • Journal of Neuroimmunology
    • The multifaceted pathogenesis of multiple sclerosis (MS) involves complex interactions between the immune and the central nervous systems which provide a multitude of targets for therapeutic interventions. Current therapies for MS are only partially effective. One potential strategy to increase treatment efficacy is the combination of two or more drugs with complementary mechanisms of action, which may result in additive or synergistic therapeutic effects. In this review, we discuss the… CONTINUE READING
    View on Elsevier
    doi.org
    13 Citations
    Background Citations
    3
    Methods Citations
    1
    Results Citations
    1

    Topics from this paper

    Explore Further: Topics Discussed in This Paper

    Paper Mentions

    Interventional Clinical Trial
    Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate
    This is a study evaluating the effect on brain volume of daily glatiramer acetate (GA) and add-on pulse steroids.  
    ConditionsRelapsing Remitting Multiple Sclerosis
    InterventionDrug
    Teva Pharmaceutical Industries
    January 2005 - May 2009
    13 Citations
    Citation Type

    Citation Type

    Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs
    • Ron Milo
    • Medicine
    • Expert opinion on pharmacotherapy
    • 2015
    • 15
    Evolution of clinical trials in multiple sclerosis
    • 15
    Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview
    • 18
    • PDF
    A case of multiple sclerosis improvement following removal of heavy metal intoxication
    • 21
    • PDF
    Network analysis of randomized controlled trials in multiple sclerosis.
    • 26
    Teriflunomide added to interferon-&bgr; in relapsing multiple sclerosis: A randomized phase II trial
    • 75
    Multiple sclerosis in Kashmir: Where we stand
    • 2
    Alterations in the cholinesterase and adenosine deaminase activities and inflammation biomarker levels in patients with multiple sclerosis
    • 28
    Analysis of single nucleotide polymorphisms with opposite effects on serum iron parameters in South African patients with multiple sclerosis
    Targeting ERK signaling pathway by polyphenols as novel therapeutic strategy for neurodegeneration.
    • 9

    References

    SHOWING 1-10 OF 87 REFERENCES
    Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis
    • 39
    Review: Innovative monoclonal antibody therapies in multiple sclerosis
    • 16
    The mechanism of action of methylprednisolone in the treatment of multiple sclerosis
    • 136
    Oral simvastatin treatment in relapsing-remitting multiple sclerosis
    • 464
    • PDF
    Combined treatment with atorvastatin and minocycline suppresses severity of EAE
    • 51
    Emerging multiple sclerosis oral therapies
    • 38
    Additive effect of the combination of glatiramer acetate and minocycline in a model of MS
    • 96
    • PDF
    Effective combination of minocycline and interferon-β in a model of multiple sclerosis
    • 72
    • PDF
    Diverse Targets for Intervention during Inflammatory and Neurodegenerative Phases of Multiple Sclerosis
    • 159
    • PDF
    Concepts of induction and escalation therapy in multiple sclerosis
    • P. Rieckmann
    • Medicine
    • Journal of the Neurological Sciences
    • 2009
    • 46